Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea ; day:26 ; month:1 ; year:2021 ; pages:1-15
Rheumatology and therapy ; (26.1.2021), 1-15
- Urheber
-
Ha, So-Young
Shim, Yoon-Bo
Lee, Min-Young
Koo, Bon-San
Kim, Jae-Hoon
Jeon, Ja-Young
Yoo, Hyun-Jeong
Kim, Young-Joo
Shin, Ju-Young
Park, Mi-Hai
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-021-00278-z
- URN
-
urn:nbn:de:101:1-2021031718572836081393
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ha, So-Young
- Shim, Yoon-Bo
- Lee, Min-Young
- Koo, Bon-San
- Kim, Jae-Hoon
- Jeon, Ja-Young
- Yoo, Hyun-Jeong
- Kim, Young-Joo
- Shin, Ju-Young
- Park, Mi-Hai
- SpringerLink (Online service)
Ähnliche Objekte (12)
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis